Hemcheck Sweden AB has signed a subscription agreement with SYNLAB Sverige AB regarding delivery of one reader and one-time tests (v-Test) for usage within training and occupational health services.

–It’s incredibly positive that we have a first customer within primary care, and more so given its SYNLAB which is a large global company active in 40 countries. The agreement has been reached after a longer period of discussions and a finalised user test. In addition, we have identified potential additional collaboration areas which we will continue to discuss. This is hopefully a first step in a broader and long-term collaboration with SYNLAB, says Joen Averstad, CEO of Hemcheck.

–We are very happy to have signed this agreement with Hemcheck regarding their point of care hemolysis detection solution. We have a strong quality focus and we continuously want to develop our organisation and the delivery of services to our customers and patients. We want to be in the forefront of development and since hemolysis is one of the most important errors in laboratory medicine, we see clear value in Hemcheck’s innovative concept. We very much look forward to the implementation, says Venus Alizadeh Theander, head of local laboratories at SYNLAB Sverige AB.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About SYNLAB

SYNLAB Group is a global company within laboratory services with more than 20 000 employees across 40 countries in 4 continents, and more than 20 billion SEK in revenues. Each year, SYNLAB performs over 500 million analyses within e.g. human medicine and veterinary medicine. SYNLAB is the market leader in medical laboratory services in Europe. In 2019, SYNLAB acquired Aleris Medilab with its central laboratory in Täby and 14 local laboratories in Stockholm. SYNLAB has since earlier four laboratories in Sweden focused on foods and environmental analyses.

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.

Important information

This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on April 20, 2020 at 14.30